FibroBiologics Statistics

Total Valuation

FibroBiologics has a market cap or net worth of $16.16 million. The enterprise value is $18.41 million.

Market Cap	16.16M
Enterprise Value	18.41M

Important Dates

The last earnings date was Friday, October 31, 2025, after market close.

Earnings Date	Oct 31, 2025
Ex-Dividend Date	n/a

Share Statistics

FibroBiologics has 61.29 million shares outstanding. The number of shares has increased by 21.49% in one year.

Current Share Class	61.29M
Shares Outstanding	61.29M
Shares Change (YoY)	+21.49%
Shares Change (QoQ)	+11.49%
Owned by Insiders (%)	12.54%
Owned by Institutions (%)	8.73%
Float	51.47M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	101.85
P/TBV Ratio	129.30
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.78, with a Debt / Equity ratio of 56.90.

Current Ratio	0.78
Quick Ratio	0.72
Debt / Equity	56.90
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2,961.83

Financial Efficiency

Return on equity (ROE) is -1,292.87% and return on invested capital (ROIC) is -192.54%.

Return on Equity (ROE)	-1,292.87%
Return on Assets (ROA)	-115.62%
Return on Invested Capital (ROIC)	-192.54%
Return on Capital Employed (ROCE)	-878.88%
Revenue Per Employee	n/a
Profits Per Employee	-$1.42M
Employee Count	13
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -89.28% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-89.28%
50-Day Moving Average	0.39
200-Day Moving Average	0.71
Relative Strength Index (RSI)	35.27
Average Volume (20 Days)	1,464,136

Short Selling Information

The latest short interest is 1.41 million, so 2.30% of the outstanding shares have been sold short.

Short Interest	1.41M
Short Previous Month	1.81M
Short % of Shares Out	2.30%
Short % of Float	2.74%
Short Ratio (days to cover)	1.34

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-17.77M
Pretax Income	-18.50M
Net Income	-18.50M
EBITDA	-17.55M
EBIT	-17.77M
Earnings Per Share (EPS)	-$0.48

Full Income Statement

Balance Sheet

The company has $4.87 million in cash and $7.11 million in debt, giving a net cash position of -$2.25 million or -$0.04 per share.

Cash & Cash Equivalents	4.87M
Total Debt	7.11M
Net Cash	-2.25M
Net Cash Per Share	-$0.04
Equity (Book Value)	125,000
Book Value Per Share	0.00
Working Capital	-1.48M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$16.30 million and capital expenditures -$361,000, giving a free cash flow of -$16.67 million.

Operating Cash Flow	-16.30M
Capital Expenditures	-361,000
Free Cash Flow	-16.67M
FCF Per Share	-$0.27

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FibroBiologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-21.49%
Shareholder Yield	-21.49%
Earnings Yield	-114.47%
FCF Yield	-103.11%

Analyst Forecast

The average price target for FibroBiologics is $10.67, which is 3,946.27% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$10.67
Price Target Difference	3,946.27%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-9.74%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1